Nyrada Inc (ASX:NYR) 57% Reduction in Total Cholesterol from Nyrada s NYX-PCSK9i In Vivo Study
57% Reduction in Total Cholesterol from Nyrada s NYX-PCSK9i In Vivo StudySydney, Dec 21, 2020 AEST (ABN Newswire) - Nyrada Inc (
ASX:NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholesterolemia (high cholesterol).
- Very encouraging preliminary in vivo efficacy results for Nyrada s oral PCSK9 inhibitor NYX-PCSK9i, showing a 57% reduction in total cholesterol
- Provides proof-of-concept in a specialised mouse model which has demonstrated high predictability of human cholesterol metabolism and cardiovascular health outcomes